Market Research Logo

Global PD-1 and PD-L1 Inhibitors Market 2019-2023

Global PD-1 and PD-L1 Inhibitors Market 2019-2023

About this market

Special drug designations to drive the market growth. One of the major benefits that some of the PD-1 and PD-L1 inhibitors have is the special drug designations given by the regulatory bodies. Many of these drugs have received designations such as breakthrough designation and fast track designation from the US FDA. the EMA. and other regulatory bodies. Vendors who have received these designations for their molecules will get certain benefits. Technavio’s analysts have predicted that the PD-1 and PD-L1 inhibitors market will register a CAGR of over 19% by 2023.

Market Overview

Increasing prevalence of cancer

Globe yearly prevalence of cancer has seen a significant rise in recent years, and the global oncology therapeutics market has witnessed the approval of various novel therapies. The gap between the demand and supply of these therapies has resulted in a huge unmet need, which has created an opportunity for vendors to conduct a study on drugs such as PD-1 and PD-L1 inhibitors.

Failures in clinical trials

The global pharmaceuticals market has witnessed a significant increase in the number of trials being conducted for checkpoint inhibitors in recent years. The top six drugs that are currently approved are also in the clinical stages for the treatment of various other cancers.

For the detailed list of factors that will drive and challenge the growth of the PD-1 and PD-L1 inhibitors market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Merck and Pfizer the competitive environment is quite intense. Factors such as the special drug designations and the increasing prevalence of cancer, will provide considerable growth opportunities to PD-1 and PD-L1 inhibitors manufactures. AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck, and Pfizer are some of the major companies covered in this report.


  • Executive summary
  • Scope of the report
    • Preface
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global pharmaceuticals market
      • Table Segments of global pharmaceuticals market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by application
    • Table Application - Market share 2018-2023 (%)
    • Comparison by application
      • Table Comparison by application
    • Solid tumors - Market size and forecast 2018-2023
      • Table Solid tumors - Market size and forecast 2018-2023 ($ millions)
      • Table Approved PD-1 and PD-L1 inhibitors for various indications: Overview
      • Table Solid tumors - Year-over-year growth 2019-2023 (%)
    • Blood-related tumors - Market size and forecast 2018-2023
      • Table Blood-related tumors - Market size and forecast 2018-2023 ($ millions)
      • Table Blood-related tumors - Year-over-year growth 2019-2023 (%)
    • Market opportunity by application
      • Table Market opportunity by application
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table New cases of cancer in US 2015
    • Market challenges
      • Table Impact of drivers and challenges
  • Market trends
    • Table PD-1 and PD-L1 inhibitors pipeline: Overview
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
    • Competitive scenario
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • AstraZeneca
      • Table AstraZeneca - Vendor overview
      • Table AstraZeneca - Business segments
      • Table AstraZeneca - Organizational developments
      • Table AstraZeneca - Geographic focus
      • Table AstraZeneca - Key offerings
      • Table AstraZeneca - Key customers
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb - Vendor overview
      • Table Bristol-Myers Squibb - Business segments
      • Table Bristol-Myers Squibb - Organizational developments
      • Table Bristol-Myers Squibb - Geographic focus
      • Table Bristol-Myers Squibb - Key offerings
      • Table Bristol-Myers Squibb - Key customers
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche - Vendor overview
      • Table F. Hoffmann-La Roche - Business segments
      • Table F. Hoffmann-La Roche - Organizational developments
      • Table F. Hoffmann-La Roche - Geographic focus
      • Table F. Hoffmann-La Roche - Segment focus
      • Table F. Hoffmann-La Roche - Key offerings
      • Table F. Hoffmann-La Roche - Key customers
    • Merck
      • Table Merck - Vendor overview
      • Table Merck - Business segments
      • Table Merck - Organizational developments
      • Table Merck - Geographic focus
      • Table Merck - Segment focus
      • Table Merck - Key Offerings
      • Table Merck - Key customers
    • Pfizer
      • Table Pfizer - Vendor overview
      • Table Pfizer - Business segments
      • Table Pfizer - Organizational developments
      • Table Pfizer - Geographic focus
      • Table Pfizer - Segment focus
      • Table Pfizer - Key offerings
      • Table Pfizer - Key customers
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report